Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation

NDT Plus

Volumn 1, Issue 3, 2008, Pages 154-156

  Levey, Seth A ^a   Bajwa, Randeep S ^a   Picken, Maria M ^a,b   Clark, Joseph I ^a   Barton, Kevin ^a   Leehey, David J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Factor V Leiden; Sunitinib; Thrombotic microangiopathy; VEGF inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; INTERLEUKIN 2; PREDNISONE; SUNITINIB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANEMIA; ARTICLE; BLOOD CHEMISTRY; BLOOD CLOTTING TEST; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY CARCINOMA; NEPHRECTOMY; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE VOLUME;

EID: 44449139979     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn013     Document Type: Article

References (14)

1. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927-1935
2. Faivre S, Delbado C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2005; 24: 25-35
3. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-l) induces proteinuria. J Biol Chem 2003; 278: 12605-12608
4. Kim YG, Suga SI, Kang DH et al. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 2000; 58: 2390-2399
5. Maroeska TLD, Bosma N, Van Hinsbergh V et al. Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS. Pediatr Nephrol 2004; 19: 754-760
6. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase (sFltl) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:600-602
7. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-1795
8. Roncone D, Satoskar A, Nadasdy T et al. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 2007; 3: 287-293
9. Kapiteijn E, Brand A, Kroep J et al. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007; 18: 1745-1747
10. Izzedine H, Brocheriou I, Deray G et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007; 22: 1481-1482
11. Frangie C, Lefaucheur C. Medioni J et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8: 177-178
12. Raife TJ, Lentz, SR, Atkinson BS et al. Factor V Leiden: A genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002; 99: 437-442
13. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. JNCI 2007; 99: 1232-1239
14. Krieg S, Studt JD, Sulzer I et al. Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency? Thromb Haemost 2005; 94: 1186-1189